Skip to main content
JoAnne Foody, MD, Cardiology, Boston, MA

JoAnneMFoodyMD

Cardiology Boston, MA

Associate Professor of Medicine, Brigham and Women's Hospital

Dr. Foody is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Foody's full profile

Already have an account?

  • Office

    75 Francis St
    Boston, MA 02115
    Phone+1 857-307-1989
    Fax+1 857-307-1955

Education & Training

  • Cleveland Clinic Foundation
    Cleveland Clinic FoundationFellowship, Cardiovascular Disease, 1996 - 2000
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 1990 - 1993
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1990

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 1992 - 2024

Awards, Honors, & Recognition

  • Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
  • Whos Who in Medicine and Healthcare Marquis Whos Who
  • Fellow (FACC) American College of Cardiology

Publications & Presentations

PubMed

Lectures

  • Preventive Cardiology Issues in Primary Care - CME Getaways Santa Monica 
    CME Getaways, New York, New York - 9/14/2012
  • 6th Annual Heart of Womens Health 
    American College of Cardiology Foundation, Washington, Dist Of Col - 1/20/2012

Press Mentions

  • European Commission Approves Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)
    European Commission Approves Yuvanci® (Single Tablet Combination Therapy [STCT] of Macitentan and Tadalafil) for Treatment of Patients with Pulmonary Arterial Hypertension (PAH)September 30th, 2024
  • Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (Bempedoic Acid) Tablet Is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad Population
    Landmark CLEAR Outcomes Study Demonstrates NEXLETOL (Bempedoic Acid) Tablet Is the Only LDL-C Lowering Therapy Since Statins to Reduce Hard Ischemic Events in a Broad PopulationApril 3rd, 2023
  • LDL May Be an Alternative to Statins
    LDL May Be an Alternative to StatinsMarch 5th, 2023
  • Join now to see all

Grant Support

  • Lipid Testing /Treatment In Older MI PatientsNational Institute On Aging2002–2005

Professional Memberships